{"id":"NCT04424316","sponsor":"Pfizer","briefTitle":"A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-17","primaryCompletion":"2023-10-27","completion":"2023-10-27","firstPosted":"2020-06-09","resultsPosted":"2025-02-11","lastUpdate":"2025-02-11"},"enrollment":14727,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Tract Infection"],"interventions":[{"type":"BIOLOGICAL","name":"RSVpreF","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"RSVpreF vaccine","type":"EXPERIMENTAL"},{"label":"Placebo dose","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.","primaryOutcome":{"measure":"Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)","timeFrame":"Within 90 days after birth","effectByArm":[{"arm":"Infant Participants: RSVpreF","deltaMin":0.7,"sd":null},{"arm":"Infant Participants: Placebo","deltaMin":1.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"0 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":464,"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","Denmark","Finland","Japan","Mexico","Netherlands","New Zealand","Philippines","South Africa","South Korea","Spain","Taiwan","The Gambia"]},"refs":{"pmids":["40872913","39746212","39746206","39733477","38853036","37018474","34774184"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C3671008"]},"adverseEventsSummary":{"seriousAny":{"events":613,"n":3698},"commonTop":["Fatigue (FATIGUE)","Headache (HEADACHE)","Injection site pain (PAIN AT INJECTION SITE)","Myalgia (MUSCLE PAIN)","Nausea (NAUSEA)"]}}